People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Other Technology, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mindstrong, Inc. | — | Other Technology | Series B | $52.0M | $944.1M | 2017 |
| Latigo Biotherapeutics, Inc. | — | Biotechnology | Series C | $50.0M | $357.5M | 2025 |
| Sequenta, Inc. | — | Other | Series B | $44.9M | $332.3M | 2013 |
| Seranova Bio, Inc. | — | Biotechnology | Series A | $15.0M | $64.0M | 2021 |
Jim Tananbaum at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jim Tananbaum on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hemant Taneja | 1 | 21 |
| LEON CHEN | 1 | 15 |
| Beth Seidenberg | 1 | 15 |
| Robert Epstein | 1 | 8 |
| Rowan Chapman | 1 | 7 |
| Richard Klausner | 1 | 7 |
| Bill Ericson | 1 | 5 |
| Nancy Stagliano | 1 | 5 |
| Kevin Raidy | 1 | 4 |
| Aaron Ring | 1 | 3 |
| Thomas Willis | 1 | 3 |
| Malek Faham | 1 | 3 |
| John Stuelpnagel | 1 | 3 |
| Tom Insel | 1 | 3 |
| Deborah Palestrant | 1 | 3 |
| Sarah London | 1 | 3 |
| Nima Farzan | 1 | 2 |
| Jacob Goldfield | 1 | 2 |
| Hui Tian | 1 | 2 |
| Beatrice McQueen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.